Evaluation of: Kavanaugh A, Ritchlin C, Rahman P et al.; on behalf of the PSUMMIT-1 and -2 Study Groups. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the Phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann. Rheum. Dis. 73(6), 1000–1006 (2014). The IL-23/IL-17 axis plays a major role in the immunopathogenesis of psoriatic arthritis (PsA), inducing the production of proinflammatory cytokines (e.g., IL-1, TNF-α, IL-6 and IL8), osteoclastogenesis and cartilage degradation. This pathway represents a novel target in the treatment of PsA. Ustekinumab is a human monoclonal antibody that prevents the human IL-12/IL-23 p40 subunit from binding to the IL12Rβ1 receptor chain. The current paper sustains that clinical efficacy of ustekinumab is associated with inhibition of radiological progression in active PsA.
Digital Object Identifier (DOI): | http://dx.doi.org/10.2217/IMT.14.39 | |
Codice identificativo ISI: | WOS:000337220000008 | |
Codice identificativo Scopus: | 2-s2.0-84902118934 | |
Handle: | http://hdl.handle.net/11695/2145 | |
URL: | http://www.ncbi.nlm.nih.gov/pubmed/24896622 | |
Titolo: | A novel biological target for the treatment of psoriatic arthritis. | |
Autori: | ||
Appare nelle tipologie: | 1.1 Articolo in rivista |